{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:38:24Z","timestamp":1792813104065,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alexion, AstraZeneca Rare Disease"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40120-025-00873-0","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T13:35:03Z","timestamp":1765632903000},"page":"383-399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Oral Corticosteroid and Nonsteroidal Immunosuppressant Therapy Use in Patients with Myasthenia Gravis Receiving Ravulizumab, Eculizumab, or Efgartigimod in the USA"],"prefix":"10.1007","volume":"15","author":[{"given":"Francesco","family":"Sacc\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Sabatella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"issue":"11","key":"873_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235","volume":"10","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10(11):2235.","journal-title":"J Clin Med"},{"issue":"8","key":"873_CR2","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German Neurological Society. J Neurol. 2016;263(8):1473\u201394.","journal-title":"J Neurol"},{"key":"873_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.nmd.2024.07.002","volume":"43","author":"KH Axelsen","year":"2024","unstructured":"Axelsen KH, Kjaer Andersen R, Andersen LK, Vissing J, Witting N. Ocular versus generalized myasthenia gravis: a continuum associated with acetylcholine receptor antibody titers. Neuromuscul Disord. 2024;43:39\u201343.","journal-title":"Neuromuscul Disord"},{"key":"873_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cen3.12739","volume":"14","author":"H Murai","year":"2023","unstructured":"Murai H, Utsugisawa K, Motomura K, Imai T, Uzawa A, Suzuki S. The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome. Clin Exp Neuroimmunol. 2023;14:19\u201327.","journal-title":"Clin Exp Neuroimmunol"},{"issue":"1","key":"873_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","volume":"1412","author":"JF Howard Jr","year":"2018","unstructured":"Howard JF Jr. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci. 2018;1412(1):113\u201328.","journal-title":"Ann N Y Acad Sci"},{"key":"873_CR6","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.8206.1","volume":"5","author":"WD Phillips","year":"2016","unstructured":"Phillips WD, Vincent A. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Res. 2016;5:F1000 Faculty Rev-513.","journal-title":"F1000Res"},{"key":"873_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596981","volume":"11","author":"K Lazaridis","year":"2020","unstructured":"Lazaridis K, Tzartos SJ. Myasthenia gravis: autoantibody specificities and their role in MG management. Front Neurol. 2020;11:596981.","journal-title":"Front Neurol"},{"issue":"3","key":"873_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"issue":"2","key":"873_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","volume":"20","author":"R Iorio","year":"2024","unstructured":"Iorio R. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies. Nat Rev Neurol. 2024;20(2):84\u201398.","journal-title":"Nat Rev Neurol"},{"key":"873_CR10","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.933296","volume":"27","author":"S Johnson","year":"2021","unstructured":"Johnson S, Katyal N, Narula N, Govindarajan R. Adverse side effects associated with corticosteroid therapy: a study in 39 patients with generalized myasthenia gravis. Med Sci Monit. 2021;27:e933296.","journal-title":"Med Sci Monit"},{"key":"873_CR11","doi-asserted-by":"publisher","first-page":"1259484","DOI":"10.3389\/fneur.2023.1259484","volume":"14","author":"L Zhen","year":"2023","unstructured":"Zhen L, Zhao X, Li W, et al. Effectiveness of early glucocorticoids in myasthenia gravis: a retrospective cohort study. Front Neurol. 2023;14:1259484.","journal-title":"Front Neurol"},{"issue":"7","key":"873_CR12","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1136\/annrheumdis-2021-221957","volume":"81","author":"M Boers","year":"2022","unstructured":"Boers M, Hartman L, Opris-Belinski D, et al. Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. Ann Rheum Dis. 2022;81(7):925\u201336.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"873_CR13","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/acr.22574","volume":"67","author":"SY Chen","year":"2015","unstructured":"Chen SY, Choi CB, Li Q, et al. Glucocorticoid use in patients with systemic lupus erythematosus: association between dose and health care utilization and costs. Arthritis Care Res (Hoboken). 2015;67(8):1086\u201394.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"873_CR14","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/art.21984","volume":"55","author":"JR Curtis","year":"2006","unstructured":"Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420\u20136.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"873_CR15","first-page":"833","volume":"22","author":"AA Dalal","year":"2016","unstructured":"Dalal AA, Duh MS, Gozalo L, et al. Dose-response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma. J Manag Care Spec Pharm. 2016;22(7):833\u201347.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1-2","key":"873_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000362727","volume":"22","author":"YG Hwang","year":"2015","unstructured":"Hwang YG, Saag K. The safety of low-dose glucocorticoids in rheumatic diseases: results from observational studies. NeuroImmunoModulation. 2015;22(1\u20132):72\u201382.","journal-title":"NeuroImmunoModulation"},{"key":"873_CR17","doi-asserted-by":"publisher","first-page":"1625457","DOI":"10.3389\/fneur.2025.1625457","volume":"16","author":"H Teranishi","year":"2025","unstructured":"Teranishi H, Tsuda K, Harada D, et al. Treatment patterns and impact of glucocorticoids on health outcomes in generalized myasthenia gravis: a retrospective observational study based on the Medical Data Vision database in Japan. Front Neurol. 2025;16:1625457.","journal-title":"Front Neurol"},{"issue":"6","key":"873_CR18","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000507","volume":"5","author":"I Lee","year":"2018","unstructured":"Lee I, Kaminski HJ, McPherson T, Feese M, Cutter G. Gender differences in prednisone adverse effects: survey result from the MG registry. Neurol Neuroimmunol Neuroinflamm. 2018;5(6):e507.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"873_CR19","unstructured":"Pfizer Inc. SOLU-MEDROL\u00ae (methylprednisolone sodium succinate). Full Prescribing Information. Pfizer Inc.; 2025."},{"key":"873_CR20","unstructured":"Shionogi Pharma, Inc. Orapred ODT\u00ae (prednisolone sodium phosphate). Full Prescribing Information. Shionogi Pharma, Inc.; 2010."},{"key":"873_CR21","unstructured":"Horizon Pharma USA, Inc. RAYOS (prednisone). Full Prescribing Information. Horizon Pharma USA, Inc; 2012."},{"issue":"1","key":"873_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cen3.12739","volume":"14","author":"H Murai","year":"2023","unstructured":"Murai H, Utsugisawa K, Motomura M, Imai T, Uzawa A, Suzuki S. The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton myasthenic syndrome. Clin Exp Neuroimmunol. 2023;14(1):19\u201327.","journal-title":"Clin Exp Neuroimmunol"},{"key":"873_CR23","doi-asserted-by":"publisher","first-page":"175628642312132","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A, et al. Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord. 2023;16:17562864231213240.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1-2","key":"873_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jns.2003.09.016","volume":"224","author":"N Kawaguchi","year":"2004","unstructured":"Kawaguchi N, Kuwabara S, Nemoto Y, et al. Treatment and outcome of myasthenia gravis: retrospective multi-center analysis of 470 Japanese patients, 1999-2000. J Neurol Sci. 2004;224(1\u20132):43\u20137.","journal-title":"J Neurol Sci"},{"key":"873_CR25","doi-asserted-by":"publisher","first-page":"175628641983224","DOI":"10.1177\/1756286419832242","volume":"12","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019;12:1756286419832242.","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"873_CR26","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/mus.26695","volume":"60","author":"G Cutter","year":"2019","unstructured":"Cutter G, Xin H, Aban I, et al. Cross-sectional analysis of the Myasthenia Gravis Patient Registry: disability and treatment. Muscle Nerve. 2019;60(6):707\u201315.","journal-title":"Muscle Nerve"},{"key":"873_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.839075","volume":"13","author":"L Di","year":"2022","unstructured":"Di L, Shen F, Wen X, et al. A randomized open-labeled trial of methotrexate as a steroid-sparing agent for patients with generalized myasthenia gravis. Front Immunol. 2022;13:839075.","journal-title":"Front Immunol"},{"key":"873_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1471-2377-11-97","volume":"11","author":"JM Heckmann","year":"2011","unstructured":"Heckmann JM, Rawoot A, Bateman K, Renison R, Badri M. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol. 2011;11:97.","journal-title":"BMC Neurol"},{"key":"873_CR29","unstructured":"Alexion Pharmaceuticals, Inc. FDA approves Soliris\u00ae (eculizumab) for the treatment of patients with generalized myasthenia gravis (gMG). https:\/\/myasthenia.org\/wp-content\/uploads\/Portals\/0\/Press%20Release%20Soliris%20FDA%20Approval.pdf. Accessed Jan 2, 2025."},{"key":"873_CR30","unstructured":"Alexion Pharmaceuticals, Inc. ULTOMIRIS\u00ae (ravulizumab-cwvz) approved in the US for adults with generalized myasthenia gravis. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/ultomiris-approved-in-the-us-for-adults-with-generalised-myasthenia-gravis.html#. Accessed Jan 2, 2025."},{"key":"873_CR31","unstructured":"Alexion Pharmaceuticals, Inc. ULTOMIRIS\u00ae (ravulizumab-cwvz). Full Prescribing Information. Alexion Pharmaceuticals; 2024."},{"key":"873_CR32","unstructured":"Alexion Pharmaceuticals, Inc. Soliris\u00ae (eculizumab). Full Prescribing Information. Alexion Pharmaceuticals, Inc.; 2025."},{"key":"873_CR33","unstructured":"UCB, Inc. UCB announces U.S. FDA approval of ZILBRYSQ\u00ae (zilucoplan) for the treatment of adults with generalized myasthenia gravis. https:\/\/www.ucb.com\/sites\/default\/files\/press_files\/8743219b260535d3.pdf. Accessed Feb 24, 2025."},{"key":"873_CR34","unstructured":"UCB, Inc. Zilbrysq\u00ae (zilucoplan). Full Prescribing Information. UCB, Inc.; 2024."},{"key":"873_CR35","unstructured":"argenx US, Inc. Argenx announces U.S. Food and Drug Administration (FDA) approval of VYVGART\u2122 (efgartigimod alfa-fcab) in generalized myasthenia gravis. https:\/\/argenx.com\/content\/dam\/argenx-corp\/media-documents\/argenx_US_gMG_PDUFA_Press_Release.pdf.coredownload.inline.pdf. Accessed Feb 24, 2025."},{"key":"873_CR36","unstructured":"argenx US, Inc. Vyvgart\u00ae (efgartigimod alfa-fcab). Full Prescribing Information. Argenx US, Inc.; 2024."},{"key":"873_CR37","unstructured":"UCB, Inc. UCB announces U.S. FDA approval of RYSTIGGO\u00ae (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis. https:\/\/www.ucb.com\/sites\/default\/files\/2023-06\/UCB%20PR%20rozanolixizumab%20FDA%20approval.pdf. Accessed Feb 24, 2025."},{"key":"873_CR38","unstructured":"UCB, Inc. Rystiggo\u00ae (rozanolixizumab-noli). Full Prescribing Information. UCB, Inc.; 2024."},{"key":"873_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.556104","volume":"11","author":"RJ Nowak","year":"2020","unstructured":"Nowak RJ, Muppidi S, Beydoun SR, O\u2019Brien FL, Yountz M, Howard JF Jr. Concomitant immunosuppressive therapy use in eculizumab-treated adults with generalized myasthenia gravis during the REGAIN open-label extension study. Front Neurol. 2020;11:556104.","journal-title":"Front Neurol"},{"issue":"4","key":"873_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70158","volume":"32","author":"TH Vu","year":"2025","unstructured":"Vu TH, Mantegazza R, Annane D, et al. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: final results from the phase\u00a03 CHAMPION MG open-label extension. Eur J Neurol. 2025;32(4):e70158.","journal-title":"Eur J Neurol"},{"issue":"17_suppl_2","key":"873_CR41","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000202372","volume":"100","author":"M Pulley","year":"2023","unstructured":"Pulley M, Macwan S, Nowak R, et al. Change in concomitant therapies for generalized myasthenia gravis in patients receiving eculizumab: a retrospective analysis of registry data (P1-5.002). Neurology. 2023;100(17_suppl_2):2183.","journal-title":"Neurology"},{"issue":"5","key":"873_CR42","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/acn3.52051","volume":"11","author":"D Tokuyasu","year":"2024","unstructured":"Tokuyasu D, Suzuki S, Uzawa A, et al. Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis. Ann Clin Transl Neurol. 2024;11(5):1338\u201346.","journal-title":"Ann Clin Transl Neurol"},{"key":"873_CR43","unstructured":"Nowak RJ, Habib AA, Scheiner CA, et al. Change in concomitant immunosuprressive therapies for generalized myasthenia gravis in patients receiving complement C5 inhibitor therapies: a retrospective analysis of registry data. Presented at: American Association of Neuromuscular & Electodiagnostic Medicine annual meeting, October 15\u201318, 2024; Savannah."},{"key":"873_CR44","unstructured":"Murai H, Mizuno M, Kondo T, et al. Long-term effectiveness and safety of eculizumab in patients with generalized myasthenia gravis (gMG): real-world data from Japan. Presented at: American Academy of Neurology annual meeting, April 5\u20139, 2025; San Diego."},{"key":"873_CR45","unstructured":"Takahashi M, Masuda M, Watanabe M, et al. Real-world experience with eculizumab in Japanese patients with myasthenia gravis: post-marketing surveillance data. Presented at: 9th congress of the European Academy of Neurology, July 1\u20134, 2023; Budapest."},{"key":"873_CR46","doi-asserted-by":"publisher","first-page":"175628642513320","DOI":"10.1177\/17562864251332037","volume":"18","author":"S Marini","year":"2025","unstructured":"Marini S, Falso S, Habetswallner F, Marini M, Iorio R. Complement inhibitor therapy as a steroid-sparing strategy in generalized myasthenia gravis. Ther Adv Neurol Disord. 2025;18:17562864251332036.","journal-title":"Ther Adv Neurol Disord"},{"key":"873_CR47","unstructured":"Nowak R, Habib A, Meisel A, et al. Concomitant immunosuppressive therapy use with Ravulizumab: Analysis of a generalized myasthenia gravis global registry. Presented at: 11th congress of the European Academy of Neurology, June 21\u201324, 2025; Helsinki."},{"issue":"18_Suppl","key":"873_CR48","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.98.18_supplement.868","volume":"98","author":"AA Habib","year":"2022","unstructured":"Habib AA, Klink A, Muppidi S, et al. Real-world eculizumab effectiveness on US patient outcomes in myasthenia gravis (ELEVATE): a retrospective chart review (S41.010). Neurology. 2022;98(18_Suppl):868.","journal-title":"Neurology"},{"issue":"2","key":"873_CR49","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3233\/JND-200584","volume":"8","author":"N Katyal","year":"2021","unstructured":"Katyal N, Narula N, Govindarajan R. Clinical experience with eculizumab in treatment-refractory acetylcholine receptor antibody-positive generalized myasthenia gravis. J Neuromuscul Dis. 2021;8(2):287\u201394.","journal-title":"J Neuromuscul Dis"},{"issue":"9","key":"873_CR50","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1007\/s00415-024-12588-7","volume":"271","author":"C Pane","year":"2024","unstructured":"Pane C, Di Stefano V, Cuomo N, et al. A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients. J Neurol. 2024;271(9):6209\u201319.","journal-title":"J Neurol"},{"key":"873_CR51","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ensci.2019.01.006","volume":"14","author":"E Amano","year":"2019","unstructured":"Amano E, Otsu S, Suzuki S, Machida A. Eculizumab improved weakness and taste disorder in thymoma-associated generalized myasthenia gravis with anti-striational antibodies: a case report. eNeurologicalSci. 2019;14:72\u20133.","journal-title":"eNeurologicalSci"},{"issue":"11","key":"873_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.9547","volume":"12","author":"S Quasthoff","year":"2024","unstructured":"Quasthoff S. Two-decade battle with myasthenia gravis: a breakthrough case report on the long-term success with eculizumab and ravulizumab treatment. Clin Case Rep. 2024;12(11):e9547.","journal-title":"Clin Case Rep"},{"issue":"4","key":"873_CR53","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/cen3.12716","volume":"13","author":"H Murai","year":"2022","unstructured":"Murai H, Suzuki S, Fukamizu Y, Osawa T, Kikui H, Utsugisawa K. Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: analysis of 1-year postmarketing surveillance. Clin Exp Neuroimmunol. 2022;13(4):280\u20139.","journal-title":"Clin Exp Neuroimmunol"},{"key":"873_CR54","doi-asserted-by":"crossref","unstructured":"Zhu G, Zhou H, Wang W, et al. Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center-real-world prospective study. Ther Adv Neurol Disord. 2025;18:17562864241311127","DOI":"10.1177\/17562864241311127"},{"issue":"6","key":"873_CR55","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1007\/s00415-024-12293-5","volume":"271","author":"L Fuchs","year":"2024","unstructured":"Fuchs L, Shelly S, Vigiser I, et al. Real-world experience with efgartigimod in patients with myasthenia gravis. J Neurol. 2024;271(6):3462\u201370.","journal-title":"J Neurol"},{"key":"873_CR56","doi-asserted-by":"crossref","unstructured":"Scheiner C, Macwan S, Streicher N, et al. Outcomes for patients with generalized myasthenia gravis prescribed ravulizumab or efgartigimod treatment: a retrospective medical record analysis (P1\u201311.001). Presented at: American Academy of Neurology annual meeting, April 5\u20139, 2025; San Diego.","DOI":"10.1212\/WNL.0000000000208765"},{"issue":"3","key":"873_CR57","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/mus.28334","volume":"71","author":"NJ Silvestri","year":"2025","unstructured":"Silvestri NJ. Individualized dosing of efgartigimod in patients with generalized myasthenia gravis: clinical experience at a single center. Muscle Nerve. 2025;71(3):422\u20138.","journal-title":"Muscle Nerve"},{"key":"873_CR58","doi-asserted-by":"publisher","first-page":"1472845","DOI":"10.3389\/fneur.2024.1472845","volume":"15","author":"T Nomura","year":"2024","unstructured":"Nomura T, Imamura M, Imura M, Mizutani H, Ueda M. Efgartigimod treatment for generalized myasthenia gravis: a single-center case series of 16 patients. Front Neurol. 2024;15:1472845.","journal-title":"Front Neurol"},{"key":"873_CR59","doi-asserted-by":"publisher","first-page":"175628642413076","DOI":"10.1177\/17562864241307687","volume":"17","author":"I Kwiedor","year":"2024","unstructured":"Kwiedor I, Menacher M, Ell\u00dfel M, Naumann M, Bayas A. First line treatment with subcutaneous efgartigimod in impending myasthenic crisis: a case report. Ther Adv Neurol Disord. 2024;17:17562864241307688.","journal-title":"Ther Adv Neurol Disord"},{"key":"873_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.123652","volume":"477","author":"N Goyal","year":"2025","unstructured":"Goyal N, Qi C, Stone J, et al. Reduction in oral glucocorticoid use after efgartigimod initiation in clinical practice among patients with generalized myasthenia gravis. J Neurol Sci. 2025;477:123652.","journal-title":"J Neurol Sci"},{"key":"873_CR61","unstructured":"ICON. The claims conundrum: integrating openness and precision for competitive advantage. ICON. https:\/\/www.iconplc.com\/insights\/value-based-healthcare\/integratedclaims. Accessed Sept 17, 2025."},{"key":"873_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152010","volume":"55","author":"JH Stone","year":"2022","unstructured":"Stone JH, McDowell PJ, Jayne DRW, et al. The glucocorticoid toxicity index: measuring change in glucocorticoid toxicity over time. Semin Arthritis Rheum. 2022;55:152010.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"873_CR63","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","volume":"76","author":"EM Miloslavsky","year":"2017","unstructured":"Miloslavsky EM, Naden RP, Bijlsma JW, et al. Development of a glucocorticoid toxicity index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017;76(3):543\u20136.","journal-title":"Ann Rheum Dis"},{"key":"873_CR64","unstructured":"Ragole T, Blackowicz M, Weiskopf E, Anand A, Sicilia M, Wolfe GI. Longitudinal associations of corticosteroid dose with corticosteroid toxicity in patients with myasthenia gravis in the USA. Presented at: Muscular dystrophy association clinical & scientific conference, March 16\u201319, 2025; Dallas."},{"key":"873_CR65","unstructured":"Goyal N, Ruck T, Hehir M, et al. Steroid toxicity in adults with myasthenia gravis in the United States based on electronic health records. Presented at: American Association of Neuromuscular & Electrodiagnostic Medicine, October 15\u201318, 2024, 2024; Savannah."},{"issue":"6","key":"873_CR66","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1530\/EJE-13-0128","volume":"168","author":"TS Han","year":"2013","unstructured":"Han TS, Krone N, Willis DS, et al. Quality of life in adults with congenital adrenal hyperplasia relates to glucocorticoid treatment, adiposity and insulin resistance: United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE). Eur J Endocrinol. 2013;168(6):887\u201393.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"873_CR67","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1046\/j.1523-1755.2003.00038.x","volume":"63","author":"PL Painter","year":"2003","unstructured":"Painter PL, Topp KS, Krasnoff JB, et al. Health-related fitness and quality of life following steroid withdrawal in renal transplant recipients. Kidney Int. 2003;63(6):2309\u201316.","journal-title":"Kidney Int"},{"issue":"4","key":"873_CR68","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419\u201325.","journal-title":"Neurology"},{"issue":"23","key":"873_CR69","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1056\/NEJMoa2501561","volume":"392","author":"RJ Nowak","year":"2025","unstructured":"Nowak RJ, Benatar M, Ciafaloni E, et al. A phase\u00a03 trial of inebilizumab in generalized myasthenia gravis. N Engl J Med. 2025;392(23):2309\u201320.","journal-title":"N Engl J Med"},{"key":"873_CR70","unstructured":"A study to investigate OCS tapering in adult participants with generalized myasthenia gravis treated with ravulizumab (OCTAGON). https:\/\/clinicaltrials.gov\/study\/NCT07221838. Accessed Nov 4, 2025."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00873-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00873-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00873-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:07:28Z","timestamp":1768403248000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00873-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["873"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00873-0","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Francesco Sacc\u00e0 has received public speaking honoraria from Alexion, AstraZeneca Rare Disease, argenx, Biogen, Genpharm, Johnson & Johnson, MedPharm, Medison Pharma, Neopharm Israel, UCB, and Zai Lab; has received compensation for advisory boards or consultation fees from Alexion, AstraZeneca Rare Disease, Amgen, argenx, AstraZeneca, Biogen, Dianthus Therapeutics, Johnson & Johnson, Lexeo Therapeutics, Novartis, Sandoz, UCB, and Zai Lab; and is a principal investigator in clinical trials for Alexion, AstraZeneca Rare Disease, argenx, Cartesian Therapeutics, Dianthus Therapeutics, Immunovant, Inc., Leadiant Biosciences, Novartis, Prilenia Therapeutics, RemeGen, and Sanofi. Justin Lee and Guido Sabatella are employees of Alexion, AstraZeneca Rare Disease and hold stock or stock options in AstraZeneca. Karen S. Yee is an employee of Alexion, AstraZeneca Rare Disease and owns shares in AstraZeneca and Takeda Pharmaceuticals. Nicholas J. Silvestri was employed at Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, at the time of the analysis and is currently an employee of Argenx and has served on a scientific advisory or data safety monitoring board for Alexion, AstraZeneca Rare Disease, Amgen, Annexon Biosciences, Immunovant, Inc., Johnson & Johnson, Regeneron, and UCB and on speaker bureaus for Alexion, AstraZeneca Rare Disease, argenx, Takeda Pharmaceuticals, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The research utilized databases that included only anonymized or de-identified information, with no individually identifiable data being collected, used, or shared. All data sources adhered to Health Insurance Portability and Accountability Act (HIPAA) guidelines. As a result, institutional review board approval was not necessary, and explicit consent or administrative authorization from individuals was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}